Refine
Document Type
- Article (4)
Language
- English (4)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Keywords
- Chemorefractory advanced gastric cancer (1)
- Danube-Tisza Interfluve (1)
- EGFR (1)
- FOLFIRI (1)
- Hif-1 alpha (1)
- PTEN (1)
- Pannonic sand steppe (1)
- Sunitinib (1)
- Tyrosine kinase inhibitor (1)
- VEGF (1)
- VEGFR (1)
- adjuvant chemotherapy (1)
- amphiregulin (1)
- calcareous Molinia meadow (1)
- dry grassland (1)
- epiregulin (1)
- heterogeneous land-scape (1)
- land use change (1)
- mowing (1)
- predictive biomarkers (1)
- species richness (1)
- stage II/III colorectal cancer (1)
- wet grasslands (1)
Institute
- Medizin (3)
Steppes used to cover large areas of Hungary, but most of this vegetation has since been destroyed. In Central Hungary, some patches have survived on ridges in wet meadows. These habitat complexes face profound land use changes and their optimal management regime is uncertain. We identified seven annually mown steppe and wet meadow types according to their grazing regime and history and aimed to answer the following questions: (1) Does grazing have beneficial effects on mown steppes and wet meadows? (2) Should the presently homogeneous management of neighbouring steppes and wet meadows be maintained? (3) Is annual mowing sufficient in assisting the recovery of steppes and wet meadows on former croplands?
We selected three localities for each of the seven vegetation types and sampled them with 50 quadrats (50 × 50 cm) in each locality, making a total of 1,050 quadrats. Vascular plant diversity relations were evaluated using the total number of species per habitat type (species richness) and the average number of species per quadrat (microsite diversity). The effect of grazing and history on microsite diversity was tested with linear mixed-effect models. We used Redundancy Analysis to disentangle the role of grazing intensity and management history on species composition. Plant species were then sorted into functional groups, and the proportions of these groups were used to evaluate community structure.
Our results indicate that mowing alone cannot maintain as high a diversity as the combination of the two land use types, thus grazing should be introduced to non-grazed areas. Steppes, however, were found more sensitive to the intensity of grazing than wet meadows. Under heavy grazing, no increased microsite diversity was detected in the steppes and the proportion of disturbance indicators tended to increase. In contrast, the same grazing intensity resulted in only positive effects in wet meadows. Thus, uniform land use on adjacent steppes and wet meadows is not recommended but intensive grazing should be stopped on steppes. Secondary steppes were less diverse than primary ones and their community structure was also poorer, whereas wet meadows had a better regeneration potential. Thus, mowing alone is an incomplete tool to restore the plant diversity of secondary steppes; they should also be grazed and/or should be supported by other active interventions.
Preclinical studies have demonstrated that the endocannabinoid system (ECS) plays an important role in the protection against intestinal inflammation and colorectal cancer (CRC); however, human data are scarce. We determined members of the ECS and related components of the ‘endocannabinoidome’ in patients with inflammatory bowel disease (IBD) and CRC, and compared them to control subjects. Anandamide (AEA) and oleoylethanolamide (OEA) were increased in plasma of ulcerative colitis (UC) and Crohn’s disease (CD) patients while 2-arachidonoylglycerol (2-AG) was elevated in patients with CD, but not UC. 2-AG, but not AEA, PEA and OEA, was elevated in CRC patients. Lysophosphatidylinositol (LPI) 18:0 showed higher levels in patients with IBD than in control subjects whereas LPI 20:4 was elevated in both CRC and IBD. Gene expression in intestinal mucosal biopsies revealed different profiles in CD and UC. CD, but not UC patients, showed increased gene expression for the 2-AG synthesizing enzyme diacylglycerol lipase alpha. Transcripts of CNR1 and GPR119 were predominantly decreased in CD. Our data show altered plasma levels of endocannabinoids and endocannabinoid-like lipids in IBD and CRC and distinct transcript profiles in UC and CD. We also report alterations for less known components in intestinal inflammation, such as GPR119, OEA and LPI.
Background: Unlike metastatic colorectal cancer (CRC) there are to date few reports concerning the predictive value of molecular biomarkers on the clinical outcome in stage II/III CRC patients receiving adjuvant chemotherapy. Aim of this study was to assess the predictive value of proteins related with the EGFR- and VEGFR- signalling cascades in these patients.
Methods: The patients' data examined in this study were from the collective of the 5-FU/FA versus 5-FU/FA/irinotecan phase III FOGT-4 trial. Tumor tissues were stained by immunohistochemistry for VEGF-C, VEGF-D, VEGFR-3, Hif-1 α, PTEN, AREG and EREG expression and evaluated by two independent, blinded investigators. Survival analyses were calculated for all patients receiving adjuvant chemotherapy in relation to expression of all makers above.
Results: Patients with negative AREG and EREG expression on their tumor had a significant longer DFS in comparison to AREG/EREG positive ones (p< 0.05). The benefit on DFS in AREG-/EREG- patients was even stronger in the group that received 5-FU/FA/irinotecan as adjuvant treatment (p=0.002). Patients with strong expression of PTEN profited more in terms of OS under adjuvant treatment containing irinotecan (p< 0.05). Regarding markers of the VEGFR- pathway we found no correlation of VEGF-C- and VEGFR-3 expression with clinical outcome. Patients with negative VEGF-D expression had a trend to live longer when treated with 5-FU/FA (p=0.106). Patients who were negative for Hif-1 α, were disease-free in more than 50% at the end of the study and showed significant longer DFS-rates than those positive for Hif-1 α (p=0.007). This benefit was even stronger at the group treated with 5-FU/FA/irinotecan (p=0.026). Finally, AREG-/EREG-/PTEN+ patients showed a trend to live longer under combined treatment combination.
Conclusions: The addition of irinotecan to adjuvant treatment with 5-FU/FA does not provide OS or DFS benefit in patients with stage II/III CRC. Nevertheless, AREG/EREG negative, PTEN positive and Hif-1 α negative patients might profit significantly in terms of DFS from a treatment containing fluoropyrimidines and irinotecan. Our results suggest a predictive value of these biomarkers concerning adjuvant chemotherapy with 5-FU/FA +/− irinotecan in stage II/III colorectal cancer.
Background: As a multi-targeted anti-angiogenic receptor tyrosine kinase (RTK) inhibitor sunitinib (SUN) has been established for renal cancer and gastrointestinal stromal tumors. In advanced refractory esophagogastric cancer patients, monotherapy with SUN was associated with good tolerability but limited tumor response.
Methods: This double-blind, placebo-controlled, multicenter, phase II clinical trial was conducted to evaluate the efficacy, safety and tolerability of SUN as an adjunct to second and third-line FOLFIRI (NCT01020630). Patients were randomized to receive 6-week cycles including FOLFIRI plus sodium folinate (Na-FOLFIRI) once every two weeks and SUN or placebo (PL) continuously for four weeks followed by a 2-week rest period. The primary study endpoint was progression-free survival (PFS). Preplanned serum analyses of VEGF-A, VEGF-D, VEGFR2 and SDF-1α were performed retrospectively.
Results: Overall, 91 patients were randomized, 45 in each group (one patient withdrew). The main grade ≥3 AEs were neutropenia and leucopenia, observed in 56 %/20 % and 27 %/16 % for FOLFIRI + SUN/FOLFIRI + PL, respectively. Median PFS was similar, 3.5 vs. 3.3 months (hazard ratio (HR) 1.11, 95 % CI 0.70–1.74, P = 0.66) for FOLFIRI + SUN vs. FOLFIRI + PL, respectively. For FOLFIRI + SUN, a trend towards longer median overall survival (OS) compared with placebo was observed (10.4 vs. 8.9 months, HR 0.82, 95 % CI 0.50–1.34, one-sided P = 0.21). In subgroup serum analyses, significant changes in VEGF-A (P = 0.017), VEGFR2 (P = 0.012) and VEGF-D (P < 0.001) serum levels were observed.
Conclusions: Although sunitinib combined with FOLFIRI did not improve PFS and response in chemotherapy-resistant gastric cancer, a trend towards better OS was observed. Further biomarker-driven studies with other anti-angiogenic RTK inhibitors are warranted.
Trial registration: This study was registered prospectively in the NCT Clinical Trials Registry (ClinicalTrials.gov) under NCT01020630 on November 23, 2009 after approval by the leading ethics committee of the Medical Association of Rhineland-Palatinate, Mainz, in coordination with the participating ethics committees (see Additional file 2) on September 16, 2009.